Haven Caldwell-Sachar, DO
Medical Oncology · Savannah, GANPI 1750677118
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), food and beverage and other — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by CTI Biopharma Corp. at 59.0% of the total. Reporting peaked in 2022 at $1,821 and has fallen 54.5% since, to $828 in 2025. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.
Across 36 payments — averaging $84.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CTI Biopharma Corp.$2K
- Adaptive Biotechnologies Corporation$218
- Novartis$199
- Gilead$150
- Seagen Inc.$123
- Merck$115
- plus $446 from 16 others
What the payments were for
- Speaking & faculty fees$1,80059%
- Food & beverage$1,03134%
- Education$211%
- Other$1997%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CTI Biopharma Corp. | 1 | $1,800 |
| Adaptive Biotechnologies Corporation | 4 | $218 |
| Novartis | 2 | $199 |
| Gilead(2 entities) | 2 | $150 |
| Seagen Inc. | 2 | $123 |
| Merck | 4 | $115 |
| AstraZeneca(2 entities) | 3 | $72 |
| Bristol Myers Squibb | 2 | $47 |
| Astellas Pharma US Inc | 2 | $45 |
| Tempus AI, Inc | 2 | $36 |
| Pfizer | 1 | $30 |
| Eisai Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Bayer | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Caris MPI, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Immunogen, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,051 in reported general payments places this provider in the 35th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 58 | $859,686 |
| ImbruvicaIbrutinib | 18 | $285,766 |
| PomalystPomalidomide | 11 | $248,197 |
| JakafiRuxolitinib Phosphate | 13 | $194,551 |
| Lenalidomide | 12 | $112,910 |
| EliquisApixaban | 82 | $59,212 |
| XgevaDenosumab | 13 | $41,081 |
| Anastrozole | 194 | $3,266 |
| Fentanyl | 16 | $1,218 |
| Dexamethasone | 39 | $1,082 |
| Ondansetron Hcl | 70 | $915 |
| Oxycodone Hcl | 87 | $849 |
| Prochlorperazine Maleate | 58 | $817 |
| Tamoxifen Citrate | 26 | $764 |
| Ondansetron OdtOndansetron | 33 | $734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $47 | $859,68658 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20 | $285,76618 claims |
| PfizerEliquis | $30 | $59,21282 claims |
| AmgenXgeva | $16 | $41,08113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Savannah
- Ovidiu NegreaSavannah$3K
- Samir KhleifAugusta$337K
- Nabil SabaAtlanta$225K
- Sreekanth ReddyVidalia$116K
- Hagop YoussoufianDecatur$78K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.